DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
Provided By GlobeNewswire
Last update: Nov 12, 2025
Châtillon, France, November 11, 2025
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
Read more at globenewswire.comNASDAQ:DBVT (12/11/2025, 2:20:25 PM)
19.43
-0.57 (-2.85%)
Find more stocks in the Stock Screener
DBVT Latest News and Analysis
